#	Pagina
attuale pagina	/open-h2020/projects/211596/index.html
-1	/open-h2020/projects/205197/index.html
-2	/open-h2020/projects/205115/index.html
-3	/open-h2020/projects/199860/index.html
-4	/open-h2020/projects/211143/index.html

Opendata, web and dolomites

DRIVE SIGNED

Development of Robust and Innovative Vaccine Effectiveness

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

DRIVE project word cloud

Explore the words cloud of the DRIVE project. It provides you a very rough idea of what is the project "DRIVE" about.

estimate private influenza respective conservative platform annually their independence drive public capacity interference agile mismatch time vaccines flexible put brand governance transparency moderate vaccination joint network fulfill risk groups preventing manner infects innovative evaluation market strains stakeholders effect immunity ve outputs scientific waning age circulating health full obligations effectiveness million positive statutes sustainable model single vaccine tools cornerstone citizens perform combining inhabitants 500 entities utilize

Project "DRIVE" data sheet

The following table provides information about the project.

Coordinator	FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA Organization address address: CALLE MICER MASCO 31 city: VALENCIA postcode: 46010 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.drive-eu.org
Total cost	9˙999˙937 €
EC max contribution	8˙999˙812 € (90%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2016-09-two-stage
Funding Scheme	IMI2-RIA
Starting year	2017
Duration (year-month-day)	from 2017-07-01 to 2022-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA Organization address address: CALLE MICER MASCO 31 city: VALENCIA postcode: 46010 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (VALENCIA)	coordinator	5˙684˙187.00
2	P95 CVBA P95 CVBA Organization address address: KONING LEOPOLD III - LAAN 1 city: LEUVEN postcode: 3001 website: www.p-95.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LEUVEN)	participant	478˙062.00
3	SYNAPSE RESEARCH MANAGEMENT PARTNERS SL SYNAPSE RESEARCH MANAGEMENT PARTNERS SL Organization address address: CALLE VELAZQUEZ 94 PLANTA 1 city: MADRID postcode: 28006 website: www.synapse-managers.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	393˙750.00
4	ISTITUTO SUPERIORE DI SANITA ISTITUTO SUPERIORE DI SANITA Organization address address: Viale Regina Elena 299 city: ROMA postcode: 161 website: http://www.iss.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	382˙500.00
5	UNIVERSITA DEGLI STUDI DI FIRENZE UNIVERSITA DEGLI STUDI DI FIRENZE Organization address address: Piazza San Marco 4 city: Florence postcode: 50121 website: http://www.unifi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (Florence)	participant	350˙812.00
6	TERVEYDEN JA HYVINVOINNIN LAITOS TERVEYDEN JA HYVINVOINNIN LAITOS Organization address address: MANNERHEIMINTIE 166 city: HELSINKI postcode: 271 website: www.thl.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (HELSINKI)	participant	349˙250.00
7	ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE (IABS-EU) ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE (IABS-EU) Organization address address: BOULEVARTD VIVIER MERLE 10-12 WORLD TRADE CENTER TOUR OXYGENE city: LYON postcode: 69393 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LYON)	participant	323˙437.00
8	UNIVERSITE LYON 1 CLAUDE BERNARD UNIVERSITE LYON 1 CLAUDE BERNARD Organization address address: BOULEVARD DU 11 NOVEMBRE 1918 NUM43 city: VILLEURBANNE CEDEX postcode: 69622 website: www.univ-Iyon1.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (VILLEURBANNE CEDEX)	participant	315˙250.00
9	INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT Organization address address: BOULEVARD DE DUNKERQUE 44 CS 90009 city: MARSEILLE postcode: 13572 website: www.ird.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (MARSEILLE)	participant	303˙687.00
10	UNIVERSITY OF SURREY UNIVERSITY OF SURREY Organization address address: Stag Hill city: GUILDFORD postcode: GU2 7XH website: www.surrey.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (GUILDFORD)	participant	257˙375.00
11	CONFEDERATION OF MENINGITIS ORGANISATIONS LTD CONFEDERATION OF MENINGITIS ORGANISATIONS LTD Organization address address: NEWMINSTER HOUSE BALDWIN STREET city: BRISTOL postcode: BS1 1LT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BRISTOL)	participant	161˙500.00
12	ABBOTT BIOLOGICALS BV ABBOTT BIOLOGICALS BV Organization address address: C.J. VAN HOUTENLAAN 36 city: WEESP postcode: 1381 CP website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (WEESP)	participant	0.00
13	GLAXOSMITHKLINE BIOLOGICALS SA GLAXOSMITHKLINE BIOLOGICALS SA Organization address address: RUE DE L INSTITUT 89 city: RIXENSART postcode: 1330 website: www.gskbio.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (RIXENSART)	participant	0.00
14	SANOFI PASTEUR SA SANOFI PASTEUR SA Organization address address: Avenue Pont Pasteur, 2 city: LYON postcode: 69007 website: www.sanofipasteur.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LYON)	participant	0.00
15	SEQIRUS UK LIMITED SEQIRUS UK LIMITED Organization address address: POINT 29 MARKET STREET city: MAIDENHEAD postcode: SL6 8AA website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (MAIDENHEAD)	participant	0.00

Map

Project objective

Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the EU. Vaccines are the cornerstone for preventing influenza and its consequences. Current influenza vaccines have a moderate variable effect, given the mismatch between vaccine and circulating strains, waning immunity and interference from previous vaccination, among others.

The single most important challenge in achieving VE studies for the various influenza vaccines put every year on the European market is the ability of the different stakeholders to work in collaboration.

To enable a sustainable network of influenza vaccine VE studies, the Development of Robust and Innovative Vaccines Effectiveness (DRIVE) main goal will be the development of a governance model between public and private entities. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes.

A second challenge will be to reach the capacity to perform vaccine brand- specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable.

Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.

Deliverables

List of deliverables.
Governance Standard Operating Procedures (SOP)	Documents, reports	2020-01-14 14:31:02
Web-based survey amongst layer 1 stakeholders	Documents, reports	2019-11-20 12:24:09
Report on the Governance SOP implementation	Documents, reports	2019-11-20 12:24:09
Report on synergies identified and collaborations developed with other initiatives	Documents, reports	2019-11-20 12:24:09
Updated and developed protocol for type- and brand- specific IVES	Documents, reports	2019-11-20 12:24:09
Report on feasible novel and innovative approaches for measuring influenza VE	Documents, reports	2019-11-20 12:24:09
Report on the collected feed-back from â€œlayer 1â€ [â€¦]	Documents, reports	2019-11-20 12:24:09
First seasonal final report of conducted studies	Documents, reports	2019-11-20 12:24:09
Updated protocol for type- and brand- specific influenza vaccine effectiveness studies (population-based database studies)	Documents, reports	2019-11-20 12:24:09
Communication report of the study milestones arising from WP7 for the use of â€œlayer 1â€ stakeholders	Documents, reports	2019-11-20 12:24:09
Annual tender for influenza vaccine effectiveness study conduct	Documents, reports	2019-11-20 12:24:09
Methodology guidelines for concerted analysis of data and control of confounding factors	Documents, reports	2019-11-20 12:24:08
Points to consider document on the interpretation of VE results	Documents, reports	2019-11-20 12:24:08
Project Handbook	Documents, reports	2019-11-20 12:24:08
Generic SAP	Documents, reports	2019-11-20 12:24:08
IT infrastructure to receive and analyse the data	Websites, patent fillings, videos etc.	2019-11-20 12:24:08
Report on the sources for usage of specific influenza vaccine brands and accessibility	Documents, reports	2019-11-20 12:24:08
Report with the definition of the ethics policies handbooks collection	Documents, reports	2019-11-20 12:24:08
Generic DMP	Documents, reports	2019-11-20 12:24:08
Standard Operating Procedures (SOPs) and templates	Documents, reports	2019-11-20 12:24:08
Multi Stake-holder Research Agenda	Documents, reports	2019-11-20 12:24:08
SWOT analysis plan and list of quality criteria	Documents, reports	2019-11-20 12:24:08
Report on the comparison of adapted local protocols and Ethical Committee evaluation in each study site	Documents, reports	2019-11-20 12:24:08
Report templates	Documents, reports	2019-11-20 12:24:08
Communication of a detailed stakeholder map for the DRIVE project	Documents, reports	2019-11-20 12:24:08
Report on the brand availability and usage of specific influenza vaccine brands	Documents, reports	2019-11-20 12:24:08
Development of the communications plan	Documents, reports	2019-11-20 12:24:08
Guideline for the identification of vaccine status and vaccine used in study participants	Documents, reports	2019-11-20 12:24:09
Report of the results of a systematic analysis on existing initiatives, tools, and/or study protocols for determining IVE [â€¦]	Documents, reports	2019-11-20 12:24:09
Electronic study support application	Websites, patent fillings, videos etc.	2019-11-20 12:24:09
Evaluation reports of how the vaccine effectiveness results could fulfil the new regulatory requirements	Documents, reports	2019-11-20 12:24:09
Written report on quality and feasibility evaluation	Documents, reports	2019-11-20 12:24:09
Agreement on communications governance model	Documents, reports	2019-11-20 12:24:09
Tailored, timely seasonal summaries of VE results for different stakeholder/clients in layer 1 and 2	Documents, reports	2019-11-20 12:24:09
Periodical back-to-back Forum of key stakeholders [â€¦]	Documents, reports	2019-11-20 12:24:09

Take a look to the deliverables list in detail: detailed list of DRIVE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DRIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DRIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors